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+ cells and colonyand whose leukocyte counts had recovered by days 8 and forming progenitor cells based on polymerase chain reac-10 after having received 1.7 × 10 7 or greater of cytokinetion (PCR) analysis were comparable for an amphotropic mobilized CD34 + PB cells/kg. Reverse transcriptase(RT)-Moloney murine leukemia virus (MLV) retroviral vector and PCR analysis of CD34 + subsets for both the GaLV and a retroviral vector derived from the gibbon ape leukemia amphotropic receptor were performed. The expression of virus (GaLV) packaging cell line, PG13. On performing the GaLV receptor was determined to be restricted to autologous transplantation studies using immunoselected CD34 + Thy-1 + cells, and both CD34 + CD38 + and CD34 + CD34 + cells transduced with the GaLV envelope (env) CD38dim cells, while the amphotropic receptor was retroviral vector, less than 1% of peripheral blood (PB) conpresent on all CD34 + cell subsets examined. Our findings tained provirus. This was true whether bone marrow (BM) suggest that, in rhesus macaques, PG13-derived retroviral or cytokine-mobilized PB immunoselected CD34
+ cells vectors may only be able to transduce a subset of CD34 + were reinfused. This level of marking was evident in two cells as only CD34
Introduction
Pluripotent hematopoietic stem cells (HSC) have the capacity to self-renew and generate progeny of both lymphoid and myeloid lineages, and as such, are particularly attractive targets for gene therapy. It is, however, quite difficult to isolate pure HSC populations. Instead, several approaches have been employed to enrich for HSC, for example, by performing immunoselections for cells that express CD34. BM, cytokine mobilized PB, and umbilical cord blood have all been used as a source of CD34 + cells for both in vitro and in vivo gene transfer studies. [1] [2] [3] [4] [5] [6] [7] [8] [9] Traditionally, gene transfer into CD34 + cells has involved ex vivo expansion of the selected cells by hematopoietic cell growth factors, such as interleukin-3 (IL-3), IL-6 and stem cell factor (SCF, c-kit ligand). These cytokines stimulate cell proliferation, an absolute requirement for retrovirus-mediated gene transfer. 6, [10] [11] [12] [13] [14] As the CD34 + cells are cultured, they are exposed to a replication-defective retroviral vector (typically an amphotropic MLV-based vector) for gene transfer. After several rounds of retrovirus-mediated gene transfer, these cells are then reinfused into a myeloablated host and the level of gene marking determined. Previous studies, both in human and nonhuman primates using a supernatant transduction protocol indicate that the levels of gene transfer obtained with amphotropic retroviral vectors is typically low (ranging from approximately 0.1% to 10%). [7] [8] [9] [15] [16] [17] In an attempt to improve upon the gene transfer efficiency, a retroviral vector was generated using the GaLV packaging cell line, PG13. This packaging cell line utilizes two expression vectors, one that expresses the MLV gag and pol genes and a second expression vector that expresses the GaLV env gene. 18 The cellular tropism as defined by the env protein of the GaLV differs from that defined by the amphotropic env protein of the MLV.
The ability of a cell to be effectively transduced by a retroviral vector is, in part, determined by the expression of the relevant retroviral receptor on the surface of the cell. Unless another alternative mechanism for vector uptake is available, then, if the appropriate receptor is not expressed by a cell, that cell will be resistant to vector transduction. Retroviral receptors constitute a group of proteins found on a cell's surface that permit the vector to bind to and subsequently transduce a cell. Several retrovirus receptors have been cloned, including the receptors for the GaLV and murine amphotropic retroviruses. 19, 20 The receptors for both the GaLV and the amphotropic retroviruses are distinct proteins encoded by separate genes with homologous functions. Both receptors function as sodium-dependent phosphate transporters. 21, 22 In addition to serving as retrovirus receptors, these proteins probably also have other important functions as they both are highly conserved and are found in such distantly related organisms as bacteria and fungi. It has previously been demonstrated that retroviral supernatant generated from the PG13 packaging cell line can successfully transduce a broad range of cell types from human and nonhuman primates in vitro. Successful transduction of the reconstituting HSC requires that this cell population both divide and express appropriate retrovirus receptors. Investigators have found that supernatant transduction using a GaLV vector can successfully transfer genes into human CD34 + cells. 23 To date, however, the expression of the GaLV receptor on subsets of CD34 + and transplantation studies using suspension cultures of GaLV env vectors have not been performed.
Results

Transduction of immunoselected CD34
+ cells Marking experiments were initiated using immunoselected rhesus CD34
+ cells and a neo gene-containing retroviral vector produced in either the GaLV (PG13/LN) or the amphotropic (PA317/G3Na) packaging cell line.
The immunoselected CD34
+ cells were transduced for 4 days in the presence of IL-6 (50 ng/ml) and SCF (100 ng/ml) at a multiplicity of infection (MOI) of approximately 10. Immediately following transduction, the cells were either harvested for genomic DNA isolation or plated for clonogenic assays. Transduction efficiencies for the cultured cells were determined by semiquantitative PCR for the neo gene. PCR analysis of the cultured cells indicated that both the GaLV and amphotropic retroviral vectors efficiently transduced the cultured cells, with approximately 50% of the cells containing the neo gene (data not shown). Similarly, hematopoietic colonies derived from these cultured cells appeared to be effectively transduced, using both PG13 or the PA317 generated vectors, with greater than 60% of the colonies containing proviral DNA sequences (Table 1) . A mock control demonstrated no evidence of background signal. + cells from the BM of three noncytokine-mobilized Rhesus macaques and the leukapheresis product (LP) of four G-CSF and SCF mobilized animals ( Table 2 ). The immunoselected CD34 + cells were transduced for 4 days in the presence of IL-6 (50 ng/ml) and SCF (100 ng/ml) at a MOI of approximately 10. Immediately following the final transduction, the cells were harvested and reinfused into the irradiated animal. The reconstitution kinetics of a control animal (RQ671) that had just received immunoselected BM-derived CD34 + cells following irradiation without viral transduction is also shown in Table 2 for comparison purposes. All seven of the transplanted animals reconstituted. All three animals reinfused with cultured BM CD34 + cells achieved a white blood cell (WBC) count of greater than 1000 cells/l 20 days following reinfusion of the transduced cells, and had a stable platelet count of greater than 50 000 cells/l an average (s.d.) of 59 (36) days following reinfusion (Table 2) . Interestingly, the four animals that were reinfused with the immunoselected CD34 + cells isolated from the cytokine-mobilized LP achieved a WBC count of greater than 1000 cells/l an average (s.d.) of 12 (4) days following reinfusion. For two of these animals (RQ927 and 90G), platelet recovery was delayed. Remarkably, however, for the two remaining animals (RQ883 and RQ1111), the platelet count never fell below 50 000 cells/l. The difference in hematopoietic reconstitution between these two groups was closely associated with the number of cultured CD34 + cells reinfused. The two animals that never experienced a platelet count of less than 50 000 cells/l and had a leukocyte count of 1000 cells/l or greater by day 10 had received a cell dose of 1.7 × 10 7 cells/kg or greater ( Table 2 ). The remaining two animals received 1.1 × 10 7 cells/kg or less. Shortly after reconstitution, PB samples were drawn from all animals and analyzed by semiquantitative PCR for the neo gene. As shown in Figure 1 , all seven animals had less than 1% of their circulating leukocytes containing detectable provirus. Control PCR analysis for ␤-actin indicated that the DNA used was equally loaded. Due to the relatively low level of marking observed in the PB, analysis of sorted populations of granulocytes and lymphocytes were not performed. The negative control was PB drawn from an untransduced animal.
Receptor analysis of CD34
+ subsets To investigate the range of expression of the GaLV receptor and MLV amphotropic receptor on subsets of CD34 + cells, RT-PCR analysis was performed on sorted subsets of CD34 + cells highly purified (98% or better).
Immunoselected populations of CD34
+ cells were sorted according to cell size (CD34 small and CD34 large), CD38 expression (CD38 + and CD38dim), and Thy-1 expression (Thy-1 + and Thy-1dim) ( Figure 2 ). 25 Total cellular RNA was isolated from pre-sorted and sorted cell populations and analyzed by RT-PCR. In bulk immunoselected CD34
+ cells, both amphotropic receptor and GaLV receptor RNA could be detected ( Figure 3 , Presort lanes). On evaluating subsets of CD34 + cells, however, differences in receptor RNA expression were observed. As shown in Figure 3 , although both amphotropic and GaLV receptor RNA could be detected in both small and large CD34
+ cells and both subpopulations of CD34 + expressing CD38, only CD34 + cells that expressed Thy-1 had detectable GaLV receptor. This is in contrast to the amphotropic receptor, in which both CD34 + Thy-1 + and CD34 + Thy-1 − cells had detectable RNA expression. Control RT-PCR analysis for ␤2-microglobulin indicated that the RNA used was efficiently reverse transcribed.
Discussion
High efficiency gene transfer into the CD34 + cells responsible for the hematopoietic reconstitution of myeloablated human and nonhuman primates has proven to be difficult. Gene transfer protocols in both human and nonhuman primates using MLV amphotropic retroviral vectors have only, at best, been successful in marking approximately 1-10% of the circulating leukocytes.
7,9,15-17 Two human trials in particular have demon- + cells were transduced with MLV retroviral vector supernatant for 6 h at 37°C in the absence of cytokines and then immediately frozen until reinfusion into the patient. Even though patient populations and transduction protocols differed between pre-clinical nonhuman primate studies and human clinical trials using MLV vectors, 7,14-17,26,27 the overall results were quite similar, ie long-term marking of a small percentage of circulating cells.
In an attempt to improve gene transfer efficiency, an alternative retroviral vector, whose tropism was determined by the GaLV env protein, was evaluated. Prior studies have reported that a GaLV retroviral vector can successfully transduce human and rhesus CD4-enriched lymphocytes in vitro, 28 and, in the latter case, be successfully reinfused into non-myeloablated rhesus macaques. 29 In addition, immunoselected human CD34 + cells have been successfully transduced in vitro, 23 and baboon immunoselected CD34
+ cells have been successfully transduced by co-culture in vitro using a GaLV-pseudotyped packaging cell line and transplanted resulting in 0.1-5% of the circulating leukocytes containing provirus. 30 Results from our colony-forming assays indicate that both the GaLV env and a MLV env retroviral vector transduced immunoselected rhesus CD34
+ cells in vitro with equal efficiencies. These in vitro transduction results, however, can be misleading in that immunoselected CD34 + cells may contain subpopulations of progenitors that contribute little to hematopoietic reconstitution, and/or may contain more mature B and T lymphocyte progenitors whose progeny is known to express the receptor. It is, therefore, reasonable to assume that cell types, other than those cells responsible for multiple lineage hematopoietic reconstitution could have been transduced in the in vitro transduction studies.
To evaluate the effectiveness of a GaLV env retroviral vector to transduce in suspension culture immunoselected CD34
+ cells that contribute to hematopoietic reconstitution, a series of transplantation studies using BMderived or cytokine-mobilized immunoselected CD34 + cells were performed. Even when there was rapid leukocyte reconstitution, less than 1% of the circulating leukocytes contained proviral DNA following autologous transplantation. These results are surprising as it would have been expected that cells contributing to rapid engraftment would be particularly susceptible to transduction with a retroviral vector. This, however, was not the case, even in two animals that had their WBC counts recover to 1000 cells/l or greater between 8 and 10 days after infusion, with their platelet counts never falling below 50 000/l. Such a rapid rate of hematopoietic recovery has not been previously observed in animals receiving comparable doses of total body ␥-irradiation and non-mobilized BM. We attribute this accelerated recovery to the reinfusion of greater numbers of immunoselected CD34
+ cells as there is a strong association between the rate of engraftment and the number of CD34 + cells reinfused. 31, 32 One possibility for the low level of detectable marked circulating leukocytes is that the GaLV receptor may be restricted to a subset of CD34 + cells. A subset that may not contribute to multilineage hematopoietic engraftment. The GaLV and amphotropic receptor are expressed at varying levels on a wide range of mouse and rat tissues. 21, 22 Rat BM, for example, has been observed to express higher RNA levels of GaLV receptor than amphotropic receptor. 21 Human immunoselected CD34 + cells also appear to be comparably transduced ex vivo by a GaLV-derived retroviral vector. 23 Our results support this observation as immunoselected rhesus CD34
+ cells were comparably transduced with a GaLV vector or with a MLV vector. Immunoselected rhesus CD34
+ cells were also found to express both the MLV amphotropic and GaLV receptor RNA. These in vitro studies, however, are potentially flawed in that the immunoselected CD34 + cells may contain other contaminating cells, such as lymphocytes and granulocytes, that could express the GaLV receptor. In addition, it is known that CD34
+ cells are heterogeneous in phenotype 33 where subsets may differentially express receptors. The observation that a GaLV env vector could effectively transduce hematopoietic colonyforming progenitors, therefore, does not necessarily mean that those cells that are responsible for multiple lineage hematopoietic reconstitution are also successfully transduced.
To evaluate the potentiality that receptor expression may differ between CD34 + subset(s), CD34 + cells were sorted based on cell size, or CD38 or Thy-1 expression. It is currently felt that cells that express CD34, Thy-1, and either no or low levels of CD38 contain the primitive HSC population. 34, 35 This observation, however, is controversial as it has been recently reported that a CD34
− cell population may contain the primitive HSC. 36 Previously, it has been shown that subsets of murine and human hematopoietic cells differentially express the ecotropic and amphotropic receptor, with murine HSCs expressing low to undetectable levels of amphotropic receptor mRNA and significantly higher levels of ecotropic receptor mRNA. 37 The level of receptor expression correlated with the marking levels observed in murine transplantation studies. These authors also observed that amphotropic receptor mRNA was expressed at lower levels in human CD34
+ CD38 − cells than CD34 + cells expressing CD38. Based on RT PCR analysis for receptor expression, in our study MLV amphotropic retrovirus receptor was expressed on all the CD34 + cell subsets evaluated. GaLV retrovirus receptor, however, was expressed solely on a population of CD34 + Thy-1 + cells that were CD38 + or CD38dim. In rhesus macaques, we have been unable to clearly identify a CD34 + CD38 − cell population. 25 This restricted expression of the GaLV receptor to CD34 + Thy-1 + cells is of interest as we have previously shown that immunoselected CD34 + Thy-1 + cells contribute predominantly to the lymphoid regeneration of nonhuman primates. 38 As the GaLV receptor is present on nonhuman primate T lymphocytes, our results further support our previous conclusion that CD34 + Thy-1 + cells may function in nonhuman primates as lymphoid progenitors.
In summary, nonhuman primates have been transplanted with CD34 + cells isolated from BM, or SCF and G-CSF-mobilized PB that were transduced with a GaLV env retroviral vector in suspension culture. Despite the rapid reconstitution using the mobilized PB CD34 + cells, less than 1% of the circulating leukocytes were marked. Interestingly, only CD34
+ Thy1 + cells transcribe the RNA The protocols were evaluated and approved by the Animal Care and Use Committee of the National Heart, Lung, and Blood Institute.
Cell culture and retroviral vectors
The packaging cell lines used for these studies were PA317 (ATCC CRL-9078) and PG13 (ATCC CRL-10686). 39 Both cell lines were grown as previously described in supplemented Dulbecco's modified Eagle's medium (DMEM). 26 Cells were cultured at 37°C in a 5% CO 2 + 95% air humidified incubator. Two similar MLV-based retroviral vectors, G3Na and LN were used for in vitro transduction experiments. 40 Both vectors are simple long terminal repeat-driven neomycin phosphotransferase type II (neo) gene-containing vectors. G3Na differs from LN by having multiple cloning sites. The LN vector was produced in PG13 packaging cells and had a titer of 7 × 10 5 G418-resistant colony-forming units (c.f.u.) per milliliter. The G3Na vector supernatant was produced in the PA317 packaging cells and had a titer of 8 × 10 5 G418-resistant c.f.u. per milliliter. The replication-defective retroviral vector utilized in the in vivo marking study has previously been described and is denoted as GC-(antiTat/Rev)SNDC24. This vector was produced in PG13 (GaLV) packaging cells and had a titer of 1.6 × 10 6 G418-resistant c.f.u. per milliliter. Viral titers were determined using HeLa cells.
BM harvest
BM collection was performed as previously described. 7 Prior to BM harvest, 100 ml of autologous PB was collected in citrate and stored at 4°C. At the time of the BM harvest, this blood was transfused into the animal. Under general anesthesia, 150-160 ml of BM was surgically harvested from both femurs, iliac crests and ischial tuberosities in heparinized syringes. Following BM harvest, the animal received a course of buprenorphine (0.1-0.3 mg/kg i.m.) for 3 days to alleviate possible bone pain.
Rhesus leukapheresis procedure
Rhesus macaques received a combination of both 100 g/kg/day granulocyte colony-stimulating factor (G-CSF) and 200 g/kg/day SCF (all kindly provided by Amgen, Thousand Oaks, CA, USA) as a subcutaneous injection for 5 days. All cytokines used for this study were pyrogen-free. The leukapheresis product (LP) was obtained from healthy rhesus macaques using a CS3000 Plus Blood Cell Separator (Baxter Healthcare, Fenwal Division, Deerfield, IL, USA) and a single, small volume chamber leukapheresis procedure that reduced the total extracorporeal volume required for the procedure to 132 ml. 25 The modifications made to the fluid path of a CS3000 Plus Blood Cell Separator permitted leukapheresis procedures to be performed on rhesus macaques weighing less than 5 kg.
Immunoselection and fluorescence-activated cell sorting CD34 + cells were immunoselected from both the BM and PB LP according to the manufacturer's instructions using the Ceprate LC-34-Biotin Kit (CellPro, Bothell, WA, USA). For sorting, the immunoselected BM and PB leukapheresis CD34
+ cells were stained with an anti-CD34-allophycocyanin (APC)-conjugated antibody, an anti-CD38-fluorescein isothiocyanate (FITC)-conjugated antibody, and an anti-Thy-1-phycoerythrin (PE)-conjugated antibody as previously described. 25 The anti-CD34 monoclonal antibody (clone 563) was a gift from Dr Gustav Gaudernack (Institution of Transplantation Immunology, Rikshospitalet, The National Hospital, Oslo, Norway) and recognizes a different CD34 epitope from that of the CellPro anti-CD34 monoclonal antibody clone used in the immunoselection procedure (clone 12.8). The CD34 clone 563 was directly conjugated to APC by Molecular Probes (Eugene, OR, USA). The anti-CD38-FITC monoclonal antibody used was the OKT10 clone (Ortho Diagnostics Raritan, NJ, USA). The anti-Thy-1-PE monoclonal antibody was the 5E10 clone from PharMingen (San Diego, CA, USA). Cells were sorted based on CD34 and CD38 expression, on CD34 and Thy-1 expression, and on CD34 expression and cell size. Cell size discrimination was based on forward and 90°light scatter. CD34
+ cell subsets were sorted to greater than 98% purity using a Coulter Elite flow cytometer (Coulter, Hialeah, FL, USA). For Figure cells/ml and cultured immediately in the presence of PG13 retroviral vector supernatant supplemented with 2 mm l-glutamine, 4 g/ml protamine sulfate, 50 ng/ml of IL-6 and 100 ng/ml SCF. The cells were refed daily with fresh retroviral supernatant for 4 days, and then resuspended in 30 ml of Hank's buffered saline solution (HBSS; Biofluids, Rockville, MD, USA) containing 10 U/ml heparin and 1% fetal calf serum (FCS) and reinfused slowly into the ␥-irradiated animal. Transduced CD34 + cells were analyzed for clonogenic activity by plating 10 3 -10 4 cells in 1 ml of HCC-4200(s) Iscove's methylcellulose (Terry Fox Laboratories, Vancouver, BC, Canada) supplemented with 2 mm l-glutamine and 10 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF), 10 ng/ml IL-3, 100 ng/ml SCF, and 2.5 U/ml erythropoietin (epo) in a 35-mm culture dish. Isolated colonies were picked and provirus was detected by 5Ј-GATAGAAGGCGATGCGCTGCGAATCG-3Ј; and 5Ј-TCCATCATGGCTG-ATGCAATGCGCTGCGAATCG-3Ј.
Autologous BM and PB transplantation procedure
The transplantation protocol used in these studies has previously been described. 7 Day 0 is designated as the day that the animal was reinfused with the cultured cells. On days −2 and −1, the animal received 6.5 Gy (dose rate: 0.1 Gy/min) total body ␥-irradiation (TBI). Standard supportive care for the BM transplant recipient was initiated the day following irradiation.
Cell purification and quantitative PCR analysis PB mononuclear (PBMN) and BM mononuclear (BMMN) cells were isolated following density centrifugation using Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). Genomic DNA was isolated from the PBMN and BMMN cells using standard techniques. 7, 26 To quantify the efficiency of gene transfer of the retroviral vector into the hematopoietic cells of the transplanted rhesus primates, dilutions of DNA from a known packaging cell line (PA317/LG11) containing a single copy of the provirus per cell was used as a standard. 7 PCR analysis was performed with 200 ng of genomic DNA from the PB and BM in the presence of ␣-32 P dCTP (3000 mCi/mmol; Amersham, Arlington Heights, IL, USA).
The sequence of the Neo primers used were as follows:
Forward: GTGAACATGCGCTGTGTGCT; Reverse:TTCTCGAGGTCGAC-GGTATC.
Equivalent loading of DNA was demonstrated by using ␤-actin primers:
5Ј␤-actin: CATTGTGATGGACTCCGGAGACGG; 3Ј␤-actin: CATCTCCTGCTCGAAGT-CTAGAGC.
Amplified products were analyzed on polyacrylamide gels, followed by drying and autoradiography using a PhosphoImager (Molecular Dynamics, Sunnyvale, CA, USA). Bands were quantified using volumetric integration by ImageQuant.
Reverse transcriptase (RT)-PCR analysis for retroviral receptors RNA expression for the amphotropic and GaLV retroviral receptor was determined on sorted subsets of CD34 + cells. Immunoselected CD34 + cells were stained and sorted according to CD34 expression and cell size, CD38 expression, or Thy-1 expression to 98% or better purity. Total cellular RNA was isolated with TRIzol reagent (Life Technologies, Grand Island, NY, USA) from the immunoselected and sorted CD34 + subsets. A total of 1 g of total cellular RNA was reverse transcribed at 42°C for 60 min with AMV-RT (Boehringer Mannheim, Indianapolis, IN, USA). One tenth of the reverse transcription product was subjected to PCR for the retroviral receptors using the following primer sets:
Ampho Forward-5Ј-CGGAACATCTTCGTGGCCTG-3Ј, Ampho Reverse-5Ј-GCTGGTCA-TGAGAGAGCCGTG-3Ј, GaLV Forward-5Ј-CCAGTACTACAGCTGC-TACC-3Ј, GaLV Reverse-5Ј-CATAGCACTGACTGAGCCGG-3Ј; and ␤2-microglobulin Forward-5Ј-CTCGCGCTACTCTCTCT TTC-3Ј, ␤2-microglobulin Reverse-5Ј-CATGTCTC-GATCCCACT TAAC-3Ј.
The PCR reactions for the amphotropic receptor mRNA were performed under the following conditions: initial denaturation at 94°C for 2 min; followed by 30 cycles of amplification with denaturation (94°C for 1 min), annealing (62°C for 1 min), elongation (72°C for 2 min); concluding with an incubation 72°C for 5 min and then cooled to 4°C. The PCR conditions for the GaLV mRNA were: initial denaturation at 94°C for 2 min; followed by 30 cycles of amplification with denaturation (94°C for 1 min), annealing (57°C for 1 min), elongation (72°C for 2 min); concluding with an incubation 72°C for 5 min and then cooled to 4°C. The PCR conditions for the ␤2-microglobulin mRNA were as follows: initial denaturation at 94°C for 2 min; followed by 30 cycles of amplification with denaturation (94°C for 1 min), annealing (58°C for 1 min), elongation (72°C for 2 min); concluding with an incubation 72°C for 5 min and then cooled to 4°C. Receptor expression on the CD34
+ cell subsets was evaluated on at least three separate occasions.
